Aripiprazole is effective in hyperprolactinemia secondary to use of Fluphenazine
Aripiprazole is drug that acts as a partial agonist at D2 and 5-HT1A receptors and antagonist at 5-HT2A receptor. It modulates the neurotransmission over activity on the dopaminergic mesolimbic pathway which is responsible for positive symptoms of Schizophrenia. Dopamine antagonism is the mechanism of action of first generation antipsychotics. In this paper we discuss an interesting case in which Aripiprazole was effective in decreasing Prolactin levels which was elevated secondary to previous Fluphenazine use.
South East Asia Journal of Public Health Vol.7(2) 2017: 40-42
Copyright (c) 2018 Smit Shah; Pooja Shah; Salman Salaria; Osman Salaria
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).